DE60027029T2 - Kombinierte impfstoffzusammensetzungen - Google Patents

Kombinierte impfstoffzusammensetzungen Download PDF

Info

Publication number
DE60027029T2
DE60027029T2 DE2000627029 DE60027029T DE60027029T2 DE 60027029 T2 DE60027029 T2 DE 60027029T2 DE 2000627029 DE2000627029 DE 2000627029 DE 60027029 T DE60027029 T DE 60027029T DE 60027029 T2 DE60027029 T2 DE 60027029T2
Authority
DE
Germany
Prior art keywords
antigen
hpv
vaccine composition
vaccine
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE2000627029
Other languages
German (de)
English (en)
Other versions
DE60027029D1 (de
Inventor
SmithKline Beecham Bio. s.a. Martine Wettendorff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
GlaxoSmithKline Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Biologicals SA filed Critical GlaxoSmithKline Biologicals SA
Application granted granted Critical
Publication of DE60027029D1 publication Critical patent/DE60027029D1/de
Publication of DE60027029T2 publication Critical patent/DE60027029T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B09—DISPOSAL OF SOLID WASTE; RECLAMATION OF CONTAMINATED SOIL
    • B09C—RECLAMATION OF CONTAMINATED SOIL
    • B09C1/00—Reclamation of contaminated soil
    • E—FIXED CONSTRUCTIONS
    • E02—HYDRAULIC ENGINEERING; FOUNDATIONS; SOIL SHIFTING
    • E02D—FOUNDATIONS; EXCAVATIONS; EMBANKMENTS; UNDERGROUND OR UNDERWATER STRUCTURES
    • E02D3/00—Improving or preserving soil or rock, e.g. preserving permafrost soil
    • E02D3/11—Improving or preserving soil or rock, e.g. preserving permafrost soil by thermal, electrical or electro-chemical means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Structural Engineering (AREA)
  • Environmental & Geological Engineering (AREA)
  • Soil Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Agronomy & Crop Science (AREA)
  • Civil Engineering (AREA)
  • Paleontology (AREA)
  • Mining & Mineral Resources (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE2000627029 1999-09-07 2000-09-07 Kombinierte impfstoffzusammensetzungen Expired - Lifetime DE60027029T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9921146 1999-09-07
GB9921146A GB9921146D0 (en) 1999-09-07 1999-09-07 Novel composition
PCT/EP2000/008784 WO2001017551A2 (en) 1999-09-07 2000-09-07 Combined vaccine compositions

Publications (2)

Publication Number Publication Date
DE60027029D1 DE60027029D1 (de) 2006-05-18
DE60027029T2 true DE60027029T2 (de) 2006-10-19

Family

ID=10860520

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2000624893 Expired - Lifetime DE60024893T2 (de) 1999-09-07 2000-09-07 Impfstoff gegen HPV
DE2000627029 Expired - Lifetime DE60027029T2 (de) 1999-09-07 2000-09-07 Kombinierte impfstoffzusammensetzungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2000624893 Expired - Lifetime DE60024893T2 (de) 1999-09-07 2000-09-07 Impfstoff gegen HPV

Country Status (33)

Country Link
US (3) US6936255B1 (enExample)
EP (3) EP1769806A3 (enExample)
JP (2) JP4689910B2 (enExample)
KR (2) KR100557665B1 (enExample)
CN (2) CN100389824C (enExample)
AR (1) AR025502A1 (enExample)
AT (2) ATE312624T1 (enExample)
AU (1) AU766494B2 (enExample)
BR (1) BR0014171A (enExample)
CA (2) CA2384064C (enExample)
CO (1) CO5280045A1 (enExample)
CY (2) CY1107457T1 (enExample)
CZ (2) CZ302811B6 (enExample)
DE (2) DE60024893T2 (enExample)
DK (2) DK1410805T3 (enExample)
ES (2) ES2261243T3 (enExample)
GB (1) GB9921146D0 (enExample)
GC (1) GC0000201A (enExample)
HK (1) HK1048435B (enExample)
HU (2) HU229099B1 (enExample)
IL (3) IL148456A0 (enExample)
MX (1) MXPA02002484A (enExample)
MY (2) MY142842A (enExample)
NO (3) NO332800B1 (enExample)
NZ (2) NZ527560A (enExample)
PL (2) PL201264B1 (enExample)
PT (1) PT1210113E (enExample)
SG (1) SG110072A1 (enExample)
SI (2) SI1210113T1 (enExample)
TR (1) TR200200607T2 (enExample)
TW (1) TWI258374B (enExample)
WO (1) WO2001017551A2 (enExample)
ZA (2) ZA200306402B (enExample)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20060029617A1 (en) * 1997-10-03 2006-02-09 Charreyre Catherine E Porcine circovirus and Helicobacter combination vaccines and methods of use
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DK1733735T3 (en) 1998-05-22 2017-06-19 Ottawa Hospital Res Inst Methods and products for the induction of mucosal immunity
US7357936B1 (en) * 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
GB9921147D0 (en) 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
ES2284559T3 (es) * 2001-03-23 2007-11-16 Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts Genes y proteinas e6 y e7 modificados del vph utiles como vacuna.
GB0110431D0 (en) * 2001-04-27 2001-06-20 Glaxosmithkline Biolog Sa Novel compounds
GB0206360D0 (en) * 2002-03-18 2002-05-01 Glaxosmithkline Biolog Sa Viral antigens
AU2003232951B2 (en) † 2002-05-17 2009-07-23 University Of Cape Town Chimaeric human papillomavirus 16 L1 proteins comprising an L2 peptide, virus-like particles prepared therefrom and a method for preparing the particles.
JP2005533855A (ja) 2002-07-24 2005-11-10 インターツェル・アクチェンゲゼルシャフト 病原性ウイルスからの別のリーディングフレームによりコードされる抗原
US7378234B2 (en) 2002-09-13 2008-05-27 Intercell Ag Method for isolating hepatitis C virus peptides
PT2241325E (pt) 2002-10-29 2012-04-12 Coley Pharm Gmbh Utilização de oligonucleótidos cpg no tratamento de infecção com vírus da hepatite c
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
US7858098B2 (en) * 2002-12-20 2010-12-28 Glaxosmithkline Biologicals, S.A. Vaccine
EP1572233B1 (en) * 2002-12-20 2011-03-30 GlaxoSmithKline Biologicals s.a. Use of HPV16 and HPV18 as vaccine against one or more of oncogenic HPV type 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68
SI1572233T1 (sl) * 2002-12-20 2011-07-29 Glaxosmithkline Biolog Sa Uporaba HPV16 in HPV18 kot cepivo proti enemu ali več onkogenih HPV tipa 31,33,35,39,45,51,52,56,58,59,66,68
ES2351489T3 (es) * 2003-03-24 2011-02-07 Intercell Ag Vacunas mejoradas.
DE602004029657D1 (de) * 2003-03-24 2010-12-02 Intercell Ag Verbesserte impfstoffe
US7758866B2 (en) * 2004-06-16 2010-07-20 Glaxosmithkline Biologicals, S.A. Vaccine against HPV16 and HPV18 and at least another HPV type selected from HPV 31, 45 or 52
MXPA06014515A (es) * 2004-06-16 2007-03-23 Glaxosmithkline Biolog Sa Vacuna contra vph16 y vph18 y al menos otro tipo de vph seleccionado de vph 31, 45 o 52.
GB0413510D0 (en) * 2004-06-16 2004-07-21 Glaxosmithkline Biolog Sa Vaccine
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
MX2007009961A (es) * 2005-02-16 2008-01-29 Novartis Vaccines & Diagnostic Composicion adyuvante que comprende fosfato de aluminio y 3d-mpl.
JP4182074B2 (ja) 2005-03-03 2008-11-19 ファナック株式会社 ハンド及びハンドリングロボット
CA2602456A1 (en) * 2005-03-23 2006-09-28 Glaxosmithkline Biologicals S.A. Composition
AU2006239471A1 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
WO2006114312A2 (en) * 2005-04-26 2006-11-02 Glaxosmithkline Biologicals S.A. Vaccine
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
US7790203B2 (en) * 2005-12-13 2010-09-07 Lowder Tom R Composition and regimen for the treatment of herpes simplex virus, herpes zoster, and herpes genitalia epidermal herpetic lesions
MX356667B (es) 2005-12-29 2018-06-08 Boehringer Ingelheim Vetmedica Inc Uso de una composicion inmunogenica de pcv2 para reducir los sintomas clinicos en cerdos.
BRPI0620859A2 (pt) 2005-12-29 2011-11-22 Boehringer Ingelheim Vetmedica, Inc. vacina de combinação multivalente contra pcv2
US20090246220A1 (en) * 2006-08-28 2009-10-01 Ertl Hildegund C J Constructs for enhancing immune responses
HUE036180T2 (hu) 2006-09-26 2018-06-28 Infectious Disease Res Inst Szintetikus adjuvánst tartalmazó vakcina készítmény
US20090181078A1 (en) 2006-09-26 2009-07-16 Infectious Disease Research Institute Vaccine composition containing synthetic adjuvant
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
AU2008226974B2 (en) 2007-03-09 2013-08-15 Merck Sharp & Dohme Llc Papillomavirus vaccine compositions
KR20150090285A (ko) 2007-06-26 2015-08-05 고에키자이단호진 휴먼 사이언스 신코우자이단 고리스크군 인간 파필로마 바이러스에 대한 교차성 중화 항체를 유도하는 백신 항원
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
EP2298344B1 (en) 2008-06-04 2016-08-17 The Chemo-Sero-Therapeutic Research Institute Use of inactivated japanese encephalitis virus particle as adjuvant
WO2010012780A1 (en) * 2008-07-31 2010-02-04 Glaxosmithkline Biologicals S.A. Vaccine against hpv
WO2010135747A1 (en) 2009-05-22 2010-11-25 Genocea Biosciences Inc. Vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
RU2732574C2 (ru) 2009-06-05 2020-09-21 Инфекшес Дизиз Рисерч Инститьют Синтетические глюкопиранозиллипидные адъюванты
KR101181907B1 (ko) * 2009-06-19 2012-09-11 아이진 주식회사 자궁경부암 백신
EA022213B1 (ru) * 2009-06-25 2015-11-30 Глаксосмитклайн Байолоджикалс С.А. Новые конструкции белка вируса папилломы человека (hpv) и их применение в предупреждении заболевания, вызываемого hpv
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2011148356A1 (en) * 2010-05-28 2011-12-01 Coley Pharmaceutical Group, Inc. Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
UA112970C2 (uk) * 2010-08-05 2016-11-25 Мерк Шарп Енд Доме Корп. Інактивований вірус вітряної віспи, спосіб його одержання і застосування
CN103154737B (zh) * 2010-08-27 2015-07-15 英特维特国际股份有限公司 疫苗制剂的效价测试
CN102008721A (zh) * 2010-11-16 2011-04-13 浙江大学 一种hpv多肽/dc混合疫苗及其制备
AU2011336894B2 (en) 2010-11-24 2016-11-17 Genocea Biosciences, Inc. Vaccines against Herpes Simplex Virus type 2: compositions and methods for eliciting an immune response
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
CN102210858B (zh) * 2011-05-18 2013-05-08 北京科兴生物制品有限公司 一种肠道病毒71型与甲型肝炎联合疫苗
US20140127260A1 (en) 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
CA2843854A1 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
US9624273B2 (en) 2011-11-23 2017-04-18 Genocea Biosciences, Inc. Nucleic acid vaccines against herpes simplex virus type 2: compositions and methods for eliciting an immune response
PT2811981T (pt) 2012-02-07 2019-06-12 Infectious Disease Res Inst Formulações adjuvantes melhoradas que compreendem os agonistas de tlr4 e os seus métodos de utilização
CN107540730B (zh) 2012-05-16 2021-07-16 免疫设计公司 用于hsv-2的疫苗
US9624510B2 (en) 2013-03-01 2017-04-18 The Wistar Institute Adenoviral vectors comprising partial deletions of E3
HK1214510A1 (zh) 2013-04-18 2016-07-29 Immune Design Corp. 用於癌症治疗的gla单一疗法
US9463198B2 (en) 2013-06-04 2016-10-11 Infectious Disease Research Institute Compositions and methods for reducing or preventing metastasis
IL310015B1 (en) 2013-12-31 2025-10-01 Access To Advanced Health Inst Single vial formulation
AU2017305176B2 (en) 2016-08-01 2021-05-27 The Wistar Institute Of Anatomy And Biology Compositions and methods of replication deficient adenoviral vectors for vaccine applications
JP2019537555A (ja) 2016-09-28 2019-12-26 ジェノセア バイオサイエンシーズ， インコーポレイテッド ヘルペスを処置するための方法および組成物
CN107987159B (zh) * 2017-11-28 2021-06-22 上海药明生物医药有限公司 一种使用大剂量dna免疫技术免疫动物使血清中抗体滴度提高的方法
GB201821207D0 (en) * 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy
CN114340665A (zh) 2019-05-25 2022-04-12 传染病研究所 用于对佐剂疫苗乳剂进行喷雾干燥的组合物和方法
CN110576034B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复方法
CN110652980B (zh) * 2019-10-09 2020-06-30 北京尚华生态环保科技股份公司 一种土壤原位修复剂
US20220396797A1 (en) 2019-11-15 2022-12-15 Infectious Disease Research Institute Rig-i agonist and adjuvant formulation for tumor treatment
CN114681602B (zh) * 2020-12-25 2023-12-01 中国食品药品检定研究院 一种双价人乳头瘤病毒疫苗
CN114796479A (zh) * 2022-06-02 2022-07-29 金宇保灵生物药品有限公司 一种畜类动物疫苗用水包油包水佐剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH085804B2 (ja) * 1988-04-28 1996-01-24 財団法人化学及血清療法研究所 Ａ型及びｂ型肝炎混合アジュバントワクチン
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
DE122007000018I1 (de) * 1991-07-19 2007-05-24 Univ Queensland Polynukleotidabschnitt des HPV16-Genoms
US5618536A (en) * 1992-09-03 1997-04-08 The United States Of America As Represented By The Department Of Health And Human Services Chimeric papillomavirus-like particles
US5437951A (en) * 1992-09-03 1995-08-01 The United States Of America As Represented By The Department Of Health And Human Services Self-assembling recombinant papillomavirus capsid proteins
EP0812593B8 (en) 1993-03-23 2010-11-10 SmithKline Beecham Biologicals S.A. Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
GB9409962D0 (en) * 1994-05-18 1994-07-06 Smithkline Beecham Biolog Novel compounds
EP0812358A1 (en) * 1995-02-24 1997-12-17 Cantab Pharmaceuticals Research Limited Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation
CA2242200A1 (en) * 1996-01-26 1997-07-31 Innogenetics N.V. Toxoplasma gondii antigen tg20
NZ331164A (en) * 1996-02-09 2000-02-28 Univ Liege Vaccines against varicella zoster virus gene 63 product
GB9711990D0 (en) * 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9717953D0 (en) * 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
CA2229955C (en) * 1998-02-20 2003-12-09 Medigene Gmbh Papilloma virus capsomere vaccine formulations and methods of use
HUP0101047A3 (en) * 1998-03-09 2004-10-28 Smithkline Beecham Biolog Combined vaccine compositions
US6500284B1 (en) 1998-06-10 2002-12-31 Suraltech, Inc. Processes for continuously producing fine grained metal compositions and for semi-solid forming of shaped articles
GB9819898D0 (en) 1998-09-11 1998-11-04 Smithkline Beecham Plc New vaccine and method of use
US7357936B1 (en) 1998-10-16 2008-04-15 Smithkline Beecham Biologicals, Sa Adjuvant systems and vaccines
ES2313881T3 (es) * 1999-02-05 2009-03-16 MERCK & CO., INC. Formulaciones de vacunas frente al papilomavirus humano.
GB9921147D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition

Also Published As

Publication number Publication date
AU766494B2 (en) 2003-10-16
CA2443214C (en) 2006-03-21
IL148456A0 (en) 2002-09-12
NO20033715L (no) 2002-04-30
US7101560B2 (en) 2006-09-05
MXPA02002484A (es) 2002-08-28
NO2012016I2 (no) 2012-10-08
NO331825B1 (no) 2012-04-10
EP1410805A1 (en) 2004-04-21
US20060280756A1 (en) 2006-12-14
PL201767B1 (pl) 2009-05-29
BR0014171A (pt) 2002-05-21
HU0303215D0 (en) 2003-11-28
HUP0303215A3 (en) 2008-04-28
NO20021116L (no) 2002-04-30
JP2003508495A (ja) 2003-03-04
CN1387443A (zh) 2002-12-25
KR100557665B1 (ko) 2006-03-06
DE60027029D1 (de) 2006-05-18
TW200408405A (en) 2004-06-01
PL201264B1 (pl) 2009-03-31
IL158107A0 (en) 2004-03-28
WO2001017551A2 (en) 2001-03-15
CY1106090T1 (el) 2011-06-08
WO2001017551A3 (en) 2001-09-27
HK1064958A1 (en) 2005-02-08
DK1210113T3 (da) 2006-07-03
EP1210113A2 (en) 2002-06-05
TR200200607T2 (tr) 2002-06-21
SG110072A1 (en) 2005-04-28
SI1210113T1 (sl) 2006-08-31
ATE321569T1 (de) 2006-04-15
EP1210113B1 (en) 2006-03-29
HUP0202804A2 (hu) 2002-12-28
HK1048435A1 (en) 2003-04-04
HU228687B1 (en) 2013-05-28
ES2253636T3 (es) 2006-06-01
IL158107A (en) 2008-11-03
CO5280045A1 (es) 2003-05-30
CY1107457T1 (el) 2012-12-19
CN100389824C (zh) 2008-05-28
NO20033715D0 (no) 2003-08-21
CA2384064A1 (en) 2001-03-15
JP2004067696A (ja) 2004-03-04
ZA200306402B (en) 2004-08-02
GC0000201A (en) 2006-03-29
HK1048435B (en) 2007-01-05
NZ527560A (en) 2004-12-24
SI1410805T1 (sl) 2006-04-30
CA2384064C (en) 2010-06-01
NO20021116D0 (no) 2002-03-06
KR100594668B1 (ko) 2006-06-30
CZ2002843A3 (cs) 2002-08-14
DE60024893T2 (de) 2006-07-06
NO332800B1 (no) 2013-01-14
PL354039A1 (en) 2003-12-15
US7220551B2 (en) 2007-05-22
CA2443214A1 (en) 2001-03-15
DE60024893D1 (de) 2006-01-19
HUP0202804A3 (en) 2004-08-30
KR20030087081A (ko) 2003-11-12
EP1410805B1 (en) 2005-12-14
US6936255B1 (en) 2005-08-30
US20040126394A1 (en) 2004-07-01
NO2012016I1 (no) 2012-10-15
CZ302811B6 (cs) 2011-11-23
HU229099B1 (en) 2013-07-29
PT1210113E (pt) 2006-07-31
MY142842A (en) 2011-01-14
JP4689910B2 (ja) 2011-06-01
TWI258374B (en) 2006-07-21
ATE312624T1 (de) 2005-12-15
ES2261243T3 (es) 2006-11-16
CN1325117C (zh) 2007-07-11
CN1618465A (zh) 2005-05-25
AR025502A1 (es) 2002-11-27
EP1769806A3 (en) 2007-10-24
KR20020027630A (ko) 2002-04-13
AU7775100A (en) 2001-04-10
MY130084A (en) 2007-05-31
GB9921146D0 (en) 1999-11-10
ZA200201810B (en) 2004-05-26
NZ517621A (en) 2003-09-26
DK1410805T3 (da) 2006-04-18
EP1769806A2 (en) 2007-04-04

Similar Documents

Publication Publication Date Title
DE60027029T2 (de) Kombinierte impfstoffzusammensetzungen
DE69933200T2 (de) Kombinierte impfstoffzusammensetzungen
DE60027440T2 (de) Impfstoff gegen hbv und hpv
AU2003236490B2 (en) Novel composition
HK1107519A (en) Vaccine against hpv
BRPI0017420B1 (pt) Composição de vacina, hpv 16 l1 e hpv 18 l1 vpl
HK1099204A (en) Vaccine against hbv and hpv

Legal Events

Date Code Title Description
8364 No opposition during term of opposition